Fidelis Care Authorization Grids Effective October 1, 2025 – Pharmacy Updates
17.09.2025
•
Posted by Provider Relations
in
Provider News
The following sections of the Fidelis Care authorization grids have been updated effective October 1, 2025.
The following codes have been updated on the Medicaid, CHP, Essential Plan, Ambetter Metal-Level Plans, and Medicare Authorization Grids and require prior authorization:
C9305 nipocalimab-aahu (Imaavy)
C9306 telisotuzumab vedotin-tllv (Emrelis)
J0614 treosulfan (Grafapex)
J1370 esomeprazole injection
J1809 fosdenopterin
J3402 remestemcel-l-rknd (Ryoncil)
J3403 Revakinagene taroretcel-lwey (Encelto)
J7173 concizumab-mtci (Alhemo)
J7174 fitusiran (Qflitlia)
J9011 datopotamab deruxtecan-dlnk (Datroway)
Q5154 omalizumab-igec (Omlyclo)
Q5155 aflibercept-jbvf (Yesafili)
Q5156 tocilizumab-anoh (Avtozma)
Q5157 denosumab-bmwo (Stoboclo/Osenvelt)
Q5158 denosumab-bnht (Bomyntra/Conexxence)
Q5159 denosumab-dssb (Ospomyv/Xbryk)
For Medicaid, CHP, Essential Plan, Ambetter Metal-Level Plans, and Medicare, the following codes have been added to the list of drugs that require NCH review:
J9011 datopotamab deruxtecan-dlnk (Datroway)
Q5156 tocilizumab-anoh (Avtozma)
Q5157 denosumab-bmwo (Stoboclo/Osenvelt)
Q5158 denosumab-bnht (Bomyntra/Conexxence)
Q5159 denosumab-dssb (Ospomyv/Xbryk)
Visit: Authorization Grids